NFATC2 and cardiac hypertrophy: For example, the pharmacological NFATc3 inhibitor A-285222 protected from endothelial dysfunction in a murine diabetes model [13] but does not block NFATc2 playing a central role in pathological myocardial hypertrophy [2].